GLP1R and cancer: Compared with the incidence of malignant neoplasia with placebo or other interventions, no increase in malignant neoplasm formation was observed with the use of GLP-1 receptor agonists (OR 1.04, 95% confidence interval (CI) 0.94–1.15; p = 0.46), liraglutide (OR 1.08, 95% CI 0.91–1.27; p = 0.38), exenatide (OR 1.00, 95% CI 0.86–1.16; p = 1.00), semaglutide (OR 0.89, 95% CI 0.35–2.22; p = 0.80), or albiglutide (OR 1.07, 95% CI 0.23–4.88; p = 0.93).